14 results on '"Affleck AJ"'
Search Results
2. Risk of chronic traumatic encephalopathy in rugby union is associated with length of playing career.
- Author
-
Stewart W, Buckland ME, Abdolmohammadi B, Affleck AJ, Alvarez VE, Gilchrist S, Huber BR, Lee EB, Lyall DM, Nowinski CJ, Russell ER, Stein TD, Suter CM, and McKee AC
- Subjects
- Humans, Rugby, Chronic Traumatic Encephalopathy, Football, Athletic Injuries complications, Athletic Injuries epidemiology
- Published
- 2023
- Full Text
- View/download PDF
3. Chronic traumatic encephalopathy in a female ex-professional Australian rules footballer.
- Author
-
Suter CM, Affleck AJ, Pearce AJ, Junckerstorff R, Lee M, and Buckland ME
- Subjects
- Humans, Female, Australia, Brain, Chronic Traumatic Encephalopathy, Football
- Published
- 2023
- Full Text
- View/download PDF
4. Past antihypertensive medication use is associated with lower levels of small vessel disease and lower Aβ plaque stage in the brains of older individuals.
- Author
-
Affleck AJ, Sachdev PS, and Halliday GM
- Subjects
- Humans, Aged, Antihypertensive Agents therapeutic use, Brain pathology, Infarction complications, Infarction pathology, Magnetic Resonance Imaging, Alzheimer Disease pathology, Cerebral Amyloid Angiopathy pathology, White Matter pathology, Leukoencephalopathies pathology, Hypertension complications, Hypertension drug therapy, Hypertension pathology, Cerebral Small Vessel Diseases complications, Cerebral Small Vessel Diseases drug therapy, Cerebral Small Vessel Diseases pathology
- Abstract
Aims: This study assesses the association of antihypertensive medication use on the severities of neuropathological cerebrovascular disease (CVD excluding lobar infarction) in older individuals., Methods: Clinical and neuropathological data were retrieved for 149 autopsy cases >75 years old with or without CVD or Alzheimer's disease and no other neuropathological diagnoses. Clinical data included hypertension status, hypertension diagnosis, antihypertensive medication use, antihypertensive medication dose (where available) and clinical dementia rating (CDR). Neuropathological CVD severity was evaluated for differences with anti-hypertensive medication usage., Results: Antihypertensive medication use was associated with less severe white matter small vessel disease (SVD, mainly perivascular dilatation and rarefaction), with a 5.6-14.4 times greater likelihood of less severe SVD if medicated. No significant relationship was detected between infarction (presence, type, number and size), lacunes or cerebral amyloid angiopathy and antihypertensive medication use. Only increased white matter rarefaction/oedema and not perivascular dilation was associated with Alzheimer's pathology, with a 4.3 times greater likelihood of reduced Aβ progression through the brain if white matter rarefaction severity was none or mild. Antihypertensive medication use was associated with reduced Aβ progression but only in those with moderate to severe white matter SVD., Conclusions: This histopathological study provides further evidence that antihypertensive medication use in older individuals is associated with white matter SVD and not with other CVD pathologies. This is mainly due to a reduction in white matter perivascular dilation and rarefaction/oedema. Even in those with moderate to severe white matter SVD, antihypertensive medication use reduced rarefaction and Aβ propagation through the brain., (© 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.)
- Published
- 2023
- Full Text
- View/download PDF
5. Quality Output Checklist and Content Assessment (QuOCCA): a new tool for assessing research quality and reproducibility.
- Author
-
Héroux ME, Butler AA, Cashin AG, McCaughey EJ, Affleck AJ, Green MA, Cartwright A, Jones M, Kiely KM, van Schooten KS, Menant JC, Wewege M, and Gandevia SC
- Subjects
- Academies and Institutes, Humans, Reproducibility of Results, Checklist, Research Report
- Abstract
Research must be well designed, properly conducted and clearly and transparently reported. Our independent medical research institute wanted a simple, generic tool to assess the quality of the research conducted by its researchers, with the goal of identifying areas that could be improved through targeted educational activities. Unfortunately, none was available, thus we devised our own. Here, we report development of the Quality Output Checklist and Content Assessment (QuOCCA), and its application to publications from our institute's scientists. Following consensus meetings and external review by statistical and methodological experts, 11 items were selected for the final version of the QuOCCA: research transparency (items 1-3), research design and analysis (items 4-6) and research reporting practices (items 7-11). Five pairs of raters assessed all 231 articles published in 2017 and 221 in 2018 by researchers at our institute. Overall, the results were similar between years and revealed limited engagement with several recommended practices highlighted in the QuOCCA. These results will be useful to guide educational initiatives and their effectiveness. The QuOCCA is brief and focuses on broadly applicable and relevant concepts to open, high-quality, reproducible and well-reported science. Thus, the QuOCCA could be used by other biomedical institutions and individual researchers to evaluate research publications, assess changes in research practice over time and guide the discussion about high-quality, open science. Given its generic nature, the QuOCCA may also be useful in other research disciplines., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
6. Chronic Traumatic Encephalopathy in a Routine Neuropathology Service in Australia.
- Author
-
Suter CM, Affleck AJ, Lee M, Davies D, Burns AL, Sy J, I'Ons B, and Buckland ME
- Subjects
- Brain pathology, Humans, Neuropathology, tau Proteins metabolism, Brain Injuries, Traumatic complications, Brain Injuries, Traumatic pathology, Chronic Traumatic Encephalopathy pathology
- Abstract
Chronic traumatic encephalopathy (CTE) is a neuropathological diagnosis defined by a unique pattern of hyperphosphorylated tau (p-tau) accumulation that begins in neocortical regions of the brain. It is associated with a range of neuropsychological symptoms, but a definitive diagnosis can only be made by postmortem brain examination. In 2018, we instituted CTE screening for all autopsy brains as part of our routine departmental protocol by performing p-tau immunohistochemistry on a restricted set of 3 neocortical blocks (frontal, temporal, and parietal). This strategy allowed us to identify 4 cases of low-stage CTE from 180 consecutive autopsies. Two of the 4 cases had a documented history of brain injury; for the remaining 2 cases, there was a long history of treatment-resistant tonic/clonic epilepsy suggesting that undocumented brain injuries may have occurred. Our experience indicates that 3-block CTE screening is useful in identifying CTE in routine practice. The results of this study further support the association between prior head injuries and CTE and demonstrate that, albeit uncommon, CTE does occur in the general population. Our findings suggest that p-tau screening should be routinely pursued in brain autopsy, particularly where there is a documented or likely history of traumatic brain injury., (© The Author(s) 2022. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
7. Chronic Traumatic Encephalopathy as a Preventable Environmental Disease.
- Author
-
Buckland ME, Affleck AJ, Pearce AJ, and Suter CM
- Abstract
In this Perspective we explore the evolution of our understanding of chronic traumatic encephalopathy (CTE) and its relationship with repetitive head injury. As with many neurodegenerative conditions, there is an imperfect correspondence between neuropathology and clinical phenotype, but unlike other neurodegenerative diseases, CTE has a discrete and easily modifiable risk factor: exposure to repetitive head injury. Consequently, evaluation of the evidence regarding exposure to repetitive head injury and CTE risk should be undertaken using public or occupational health frameworks of medical knowledge. The current debate over the existence of CTE as a disease of concern is fuelled in part by immediate medico-legal considerations, and the involvement of high-profile athletes, with inevitable media interest. Moving beyond this debate has significant potential to address and reduce disease impact in the near future, and provide novel insights into mechanisms underlying abnormal protein accumulation in CTE and other neurodegenerative diseases., Competing Interests: AP currently receives partial research salary funding from Erasmus+ strategic partnerships program (2019-1-IE01-KA202-051555). AP has previously received partial research funding from the Sports Health Check Charity (Australia), Australian Football League, Impact Technologies Inc., and Samsung Corporation, and was remunerated for expert advice to medico-legal practices. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Buckland, Affleck, Pearce and Suter.)
- Published
- 2022
- Full Text
- View/download PDF
8. Chronic traumatic encephalopathy in Australia: the first three years of the Australian Sports Brain Bank.
- Author
-
Suter CM, Affleck AJ, Lee M, Pearce AJ, Iles LE, and Buckland ME
- Subjects
- Australia epidemiology, Brain diagnostic imaging, Humans, Chronic Traumatic Encephalopathy diagnosis, Sports
- Published
- 2022
- Full Text
- View/download PDF
9. A Practical Approach to Differentiate the Frontotemporal Tauopathy Subtypes.
- Author
-
Forrest SL, Halliday GM, Sizemova A, van Roijen M, McGinley CV, Bright F, Kapur M, McGeachie AB, McCann H, Shepherd CE, Tan RH, Affleck AJ, Huang Y, and Kril JJ
- Subjects
- Aged, Aged, 80 and over, Brain pathology, Female, Humans, Male, Middle Aged, Reproducibility of Results, Frontotemporal Lobar Degeneration classification, Frontotemporal Lobar Degeneration pathology, Tauopathies classification, Tauopathies pathology
- Abstract
This study proposes a practical approach, using the minimum number of brain regions and stains, to consolidate previously published neuropathological criteria into one operationalized schema to differentiate subtypes of frontotemporal lobar degeneration with tau-immunopositive inclusions (FTLD-tau). This approach uses the superior frontal and precentral cortices and hippocampus stained for phosphorylated-tau, p62 and modified Bielschowsky silver, and the midbrain stained only for modified Bielschowsky silver. Accuracy of interrater reliability was determined by 10 raters in 24 FTLD-tau cases (Pick disease = 4, corticobasal degeneration = 9, progressive supranuclear palsy = 5, globular glial tauopathy = 6) including 4 with a mutation in MAPT collected with consent by Sydney Brain Bank. All brain regions and stains assessed proved informative for accurate pathological subtyping, and many neuropathological features were identified as common across the FTLD-tau subtypes. By identifying subtype-specific neuropathological features in the sections selected, 10 independent observers assigned the cases to a FTLD-tau subtype with almost perfect agreement between raters, emphasizing the requirement for the assessment of subtype-specific features for the accurate subtyping of FTLD-tau. This study consolidates current consensus diagnostic criteria for classifying FTLD-tau subtypes with an efficient, simple and accurate approach that can be implemented in future clinicopathological studies., (© 2020 American Association of Neuropathologists, Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
10. Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation.
- Author
-
Affleck AJ, Sachdev PS, Stevens J, and Halliday GM
- Abstract
Introduction: Mounting evidence supports an association between antihypertensive medication use and reduced risk of Alzheimer's disease (AD). Consensus on possible pathological mechanisms remains elusive., Methods: Human brain tissue from a cohort followed to autopsy that included 96 cases of AD (46 medicated for hypertension) and 53 pathological controls (33 also medicated) matched for cerebrovascular disease was available from the New South Wales Brain Banks. Quantified frontal cortex amyloid beta (Aβ) and tau proteins plus Alzheimer's neuropathologic change scores were analyzed., Results: Univariate analyses found no difference in amounts of AD proteins in the frontal cortex between medication users, but multivariate analyses showed that antihypertensive medication use was associated with a less extensive spread of AD proteins throughout the brain., Discussion: The heterogeneous nature of the antihypertensive medications is consistent with downstream beneficial effects of blood pressure lowering and/or management being associated with the reduced spreading of AD pathology observed., Competing Interests: AA is a recipient of UNSW Brain Sciences Collaborative PhD Grant. PS is supported by research grants from the National Health & Medical Research Council, the Australian Research Council, the National Institute of Aging, the NHMRC National Institute for Dementia Research, and several philanthropic foundations. He reports no conflicts of interest in relation to this work. JS is funded by a research grant from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health (AA012725). GH consults for the National Health and Medical Research Council of Australia (NHMRC); received travel funds from AAIC, Int Soc Neurochemistry, Int DLB Conference, AAN, Int MSA Conference, NHMRC National Institute for Dementia Research, Japanese Neurology Soc; is on the editorial boards of Acta Neuropathol, J Neural Transm, J Parkinson Dis, Transl Neurodegen, Neuropathol Appl Neurobiol, receives royalties from Academic press, Elsevier & Oxford University Press; receives research grant funding from NHMRC, MJ Fox Foundation, Shake‐it‐up Australia, Parkinson's NSW, University of Sydney (infrastructure & equipment); and holds stock in Cochlear (2004 on) & NIB Holdings (2007 on)., (© 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Published
- 2020
- Full Text
- View/download PDF
11. Alzheimer's amyloid-β and tau protein accumulation is associated with decreased expression of the LDL receptor-associated protein in human brain tissue.
- Author
-
Shepherd CE, Affleck AJ, Bahar AY, Carew-Jones F, Gregory G, Small DH, and Halliday GM
- Subjects
- Amyloid beta-Peptides metabolism, Animals, Humans, LDL-Receptor Related Protein-Associated Protein, Alzheimer Disease, Brain metabolism, tau Proteins metabolism
- Abstract
Introduction: One of the major neuropathological features of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) protein in the brain. Evidence suggests that the low-density lipoprotein receptor-associated protein (RAP) binds strongly to Aβ and enhances its cellular uptake and that decreased RAP expression correlates with increased Aβ production in animal models of AD., Methods: The current study examined whether RAP levels change in AD human brain tissue and whether they are related to the amount of AD pathology. RAP and NeuN levels were determined by Western blot, while low-density lipoprotein receptor-related protein 1 (LRP1), tau and Aβ levels were determined by ELISA in the temporal cortex of 17 AD and 16 control cases., Results: An increase in total Aβ and insoluble and soluble tau protein was observed in AD brain tissue. In contrast, RAP levels were significantly decreased in AD brain tissue compared to controls. Correlation analysis revealed that levels of RAP correlated with both total Aβ and soluble and insoluble tau levels. Neither LRP1 nor NeuN levels were significantly altered in AD brain tissue homogenates and did not correlate with Aβ or tau protein levels., Conclusion: Reduction in RAP may contribute to the accumulation and aggregation of Aβ in the AD brain., (© 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
12. Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both Aβ and tau pathology.
- Author
-
Shepherd CE, Affleck AJ, Bahar AY, Carew-Jones F, and Halliday GM
- Subjects
- Aged, Aged, 80 and over, Alzheimer Disease pathology, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neurons pathology, Alzheimer Disease etiology, Alzheimer Disease metabolism, Amyloid beta-Peptides metabolism, Clusterin metabolism, Peptide Fragments metabolism
- Abstract
Clusterin (CLU) is a pleiotropic glycoprotein that exists as a secreted, neuroprotective or intracellular, neurotoxic form, both of which increase in Alzheimer's disease (AD) causing increased Aβ42 deposition. No studies have assessed the association between functionally distinct alloforms of CLU and tau protein or neuronal loss, despite its intracellular toxicity. We confirm previous reports of significant increases in both intracellular CLU and secreted CLU in the brain tissue of individuals with AD (p < 0.01) and show no association with neuronal loss. The increase in CLU alloforms was most closely associated with increases in both insoluble Aβ42 and tau protein (p = 0.001), supporting its role in AD pathogenesis. Further research should investigate whether altering human CLU levels may have viability as a therapeutic option for AD., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. Condensing the Aβ protocol to reduce the effort and cost of NIA-AA guidelines for neuropathologic assessment of Alzheimer disease.
- Author
-
Shepherd CE, McGeachie AB, Affleck AJ, and Halliday GM
- Subjects
- Humans, Neuropathology, Alzheimer Disease, Nervous System Diseases
- Published
- 2019
- Full Text
- View/download PDF
14. Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration.
- Author
-
Forrest SL, Crockford DR, Sizemova A, McCann H, Shepherd CE, McGeachie AB, Affleck AJ, Carew-Jones F, Bartley L, Kwok JB, Kim WS, Jary E, Tan RH, McGinley CV, Piguet O, Hodges JR, Kril JJ, and Halliday GM
- Subjects
- Aged, Aged, 80 and over, Brain pathology, C9orf72 Protein genetics, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Female, Frontotemporal Lobar Degeneration genetics, Frontotemporal Lobar Degeneration pathology, Frontotemporal Lobar Degeneration physiopathology, Humans, Lewy Body Disease genetics, Lewy Body Disease pathology, Lewy Body Disease physiopathology, Male, Middle Aged, Multiple System Atrophy genetics, Multiple System Atrophy pathology, Parkinsonian Disorders genetics, Parkinsonian Disorders pathology, Parkinsonian Disorders physiopathology, Prevalence, Progranulins genetics, alpha-Synuclein metabolism, tau Proteins genetics, tau Proteins metabolism, Frontotemporal Lobar Degeneration epidemiology, Lewy Body Disease epidemiology, Multiple System Atrophy physiopathology
- Abstract
Objective: To investigate the prevalence of clinically relevant multiple system atrophy (MSA) and Lewy body disease (LBD) pathologies in a large frontotemporal lobar degeneration (FTLD) cohort to determine if concomitant pathologies underlie the heterogeneity of clinical features., Methods: All prospectively followed FTLD-tau and FTLD-TDP cases held by the Sydney Brain Bank (n = 126) were screened for coexisting MSA and LBD (Braak ≥ stage IV) pathology. Relevant clinical (including family history) and genetic associations were determined., Results: MSA pathology was not identified in this series. Of the FTLD cohort, 9 cases had coexisting LBD ≥ Braak stage IV and were associated with different FTLD subtypes including Pick disease (n = 2), corticobasal degeneration (n = 2), progressive supranuclear palsy (n = 2), and TDP type A (n = 3). All FTLD-TDP cases with coexisting LBD had mutations in progranulin (n = 2) or an abnormal repeat expansion in C9orf72 (n = 1). All FTLD-tau cases with coexisting LBD were sporadic. The H1H1 MAPT haplotype was found in all cases that could be genotyped (n = 6 of 9). Seven cases presented with a predominant dementia disorder, 3 of which developed parkinsonism. Two cases presented with a movement disorder and developed dementia in their disease course. The age at symptom onset (62 ± 11 years) and disease duration (8 ± 5 years) in FTLD cases with coexisting LBD did not differ from pure FTLD or pure LBD cases in the brain bank., Conclusion: Coexisting LBD in FTLD comprises a small proportion of cases but has implications for clinical and neuropathologic diagnoses and the identification of biomarkers., (© 2019 American Academy of Neurology.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.